1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Emcure Pharmaceuticals Ltd.

Emcure Pharmaceuticals Ltd.

EMCURE.NS
Emcure Pharmaceuticals Ltd.IN flagNational Stock Exchange of India
1,835.90
INR
+0.90
- -
348.23BMarket Cap

Total Valuation

Emcure Pharmaceuticals Ltd. carries a market capitalization of 348.23B, placing it among publicly traded companies globally. Its enterprise value stands at 315.80B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap348.23B
Enterprise Value315.80B

Share Statistics

Emcure Pharmaceuticals Ltd. currently has 189.59M shares outstanding.

Shares Outstanding189.59M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Emcure Pharmaceuticals Ltd. trades at a trailing price-to-earnings ratio of 32.72. The price-to-sales ratio is 3.29, and the price-to-book ratio stands at 159.55.

PE Ratio32.72
PS Ratio3.29
PB Ratio159.55
P/TBV Ratio7.80
P/FCF RatioN/A
P/OCF RatioN/A

Enterprise Valuation

On an enterprise value basis, Emcure Pharmaceuticals Ltd. trades at an EV/EBITDA multiple of 22.99 and an EV/FCF ratio of 300.58. The EV/Sales ratio of 3.43 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 22.99 provides insight into valuation relative to core operating earnings.

EV / Sales3.43
EV / EBITDA22.99
EV / EBIT22.99
EV / FCF300.58

Financial Position

Emcure Pharmaceuticals Ltd. maintains a current ratio of 1.43, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 30.57, indicating elevated leverage, while an interest coverage ratio of 9.56 demonstrates adequate ability to service its debt obligations.

Current Ratio1.43
Quick Ratio0.06
Debt / Equity30.57
Debt / EBITDA1.11
Interest Coverage9.56

Financial Efficiency

Emcure Pharmaceuticals Ltd. posts a return on equity of 50.07 and a return on invested capital of 16.30.

Return on Equity (ROE)50.07
Return on Assets (ROA)10.36
Return on Invested Capital (ROIC)16.30
Return on Capital Employed (ROCE)31.36
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.69

Taxes

Over the trailing twelve months, Emcure Pharmaceuticals Ltd. has paid 3.46B in income taxes, reflecting an effective tax rate of 26.87.

Income Tax3.46B
Effective Tax Rate26.87

Stock Price Statistics

Emcure Pharmaceuticals Ltd.'s stock has gained approximately 47.68723% over the past 52 weeks. The 50-day moving average sits at 1,733.64, while the 200-day moving average is 1,526.11.

Beta (5Y)N/A
52-Week Price Change47.68723%
50-Day Moving Average1,733.64
200-Day Moving Average1,526.11
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Emcure Pharmaceuticals Ltd. generated 92.04B in revenue and converted that into 9.24B in net income, yielding earnings per share of 49.66. EBITDA reached 13.74B, while operating income came in at 13.74B.

Revenue92.04B
Gross Profit55.46B
Operating Income13.74B
Pretax Income12.87B
Net Income9.24B
EBITDA13.74B
EBIT13.74B
Earnings Per Share (EPS)49.66

Balance Sheet

Emcure Pharmaceuticals Ltd. holds 2.16B in cash and equivalents against 15.21B in total debt, resulting in a net debt position of 10.67B. Total book value stands at 1.90B, with working capital of 17.00B providing operational flexibility.

Cash & Cash Equivalents2.16B
Total Debt15.21B
Net Debt10.67B
Equity (Book Value)1.90B
Book Value Per Share10.00
Working Capital17.00B

Margins

Emcure Pharmaceuticals Ltd. operates with a gross margin of 60.26, reflecting its pricing power and cost economics. The operating margin of 14.92 and net profit margin of 10.04 provide insight into operational efficiency.

Gross Margin60.26
Operating Margin14.92
Pretax Margin13.99
Profit Margin10.04
EBITDA Margin14.92

Scores

Emcure Pharmaceuticals Ltd. posts an Altman Z-Score of 5.77, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score5.77